Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SA, Be careful what you wish for…. and, then miss out…. JMHO GLTA!
Crapola2rheleft, It is available in the Hycroft March newsletter released today. I couldn’t get the link to transfer to ihub. It’s available also on you tube.
New video available…
New video available…
Hycroft’s Monthly Update
March 2024
Welcome back to Hycroft’s monthly newsletter!
Gold is heating up and it has been a busy month at Hycroft with a lot of work happening behind the scenes. We are advancing the metallurgical testwork for the technical study expected mid-year, modelling the resource including the new high-grade silver intercepts from the 2023 drill program, and executing the follow up drill program to those spectacular results. We have also been hitting the road, with marketing trips to Toronto and New York as well as attending the invite-only BMO Global Metals and Mining Conference and the PDAC, the largest mining conference in the world.
See below some photos from site and check out our new investor presentation, plus some additional tidbits from the industry to help you on your investing journey. Have questions? Reach out any time (contact information below) as we are always happy to hear from investors and answer questions. Until next time!
Recent Photos from Site
Have a look at the picture essay we put together for this issue where we take you behind the scenes of Hycroft’s operations. In about one minute you will tour the rugged landscape that surrounds the mine, take a tour of our drilling and coring operations, our assay lab and the core shed.
These picture are fresh off the press after our CEO, Diane Garrett’s visit to site. We hope you enjoy the tour!
WATCH VIDEO
Sorry, the video link didn’t transfer…
New video available…
lakers17, let’s see how he does…. eom
Chartmaster, Thanks for the reply… apparently, this is a very fluid and volatile situation… it should be exciting at least … good luck to all!!
Chartmaster, What and when would be “your” entry point on Monday morning? Seriously…
BIO-key International, Inc. (NASDAQ:BKYI) shares crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $4.36 and traded as low as $1.80. BIO-key International shares last traded at $1.90, with a volume of 39,816 shares traded.
BIO-key International Trading Down 5.9 %
The company has a current ratio of 1.30, a quick ratio of 0.59 and a debt-to-equity ratio of 0.07. The stock has a fifty day simple moving average of $1.98 and a 200 day simple moving average of $4.36.
Mutat, Then again, what would shareholders of BP say if management could increase their shareholder share price by 20,000%? That’s at where Enzolytics, Inc. is…. If you think that is ludicrous, multiply each cure individually, then combine the value.
I’m sitting back just watching it happen….
Mutat, Agree. … eom
sspalmo, $1T may be a stretch for now, but with cures for 21 different diseases, each clinical trial could eventually add up to that value, and I’m not kidding… with the right licensing, this company could eventually achieve that market cap… JMHO GLTA!
suny66, I disagree, Things here have, and, continue to improve. Although, the SAGA deal fell through (some consider it a good thing), it is an indication of value here ($450M) initially. Since then, the IP value has increased. The next offer could easily be $1B or higher… only Charles knows the options.
I expect a PR from ENZC once the SAGA deal is officially canceled. GLTA!
mineanddine, Have taken profits along the way here, and any shares I trade are all at zero cost for over two years now. It’s good to be sitting in a “no risk rocking chair” just watching it all happen. I have even given hundreds of thousands of shares to my children. It’s all easy now… GLTA!
RSI = 28.61…. eom
Thanks to whoever dumped those millions in that market order just now… picked up 758k shares @. 012…
ATM123, Eco-Tek Group , Inc. initially filed with the Arizona SOS on 2/15/2022. That’s officially when Hoffman (Emergent) took over.
ATM223, It could be a chance to pick up some cheap shares, as Hariton is typically paid in shares and he usually dumps them into the market quickly after receiving them.
ATM123, Routine required filling for maintaining “Current” status.
Attorney Later filed… https://www.otcmarkets.com/otcapi/company/financial-report/394284/content
Let me look into it.A lot of entities have reached out with an interest in our science, especially the AI platform. Hopefully, we can do podcasts with focused topics rather than updates that will be provided through IR firm, disclosures, and press releases.
— Gaurav Chandra M.D. (@drgauravchandra) March 12, 2024
DUBAI, United Arab Emirates, March 11, 2024 (GLOBE NEWSWIRE) -- Humanity International Investments announces significant milestones in its innovative Humanity Protocol initiative. Over 40,000 NFTs have been claimed to date, showcasing the project making remarkable strides in digital identity and blockchain technology integration.
Humanity International Investments, under the Chairmanship of His Highness, Sheikh Marwan bin Mohamed bin Rashid Al Maktoum, launched a blockchain-based economic empowerment initiative, the Humanity Protocol, and strategically partnered with BIO-key (Nasdaq: BKYI), a leader in Identity and Access Management solutions including biometric palm scan authentication.
This collaboration will enable individuals, particularly in Africa, to authenticate their identities through a palm scan to securely claim their digital footprint through a Non-Fungible Token (NFT). The innovative approach not only enhances security and privacy in digital transactions but empowers individuals by providing them with a verified and immutable digital identity, marking a significant step forward in the integration of biometric technology with blockchain for identity verification. To date, the partnership has already garnered approximately 15,000 palm scans with plans to verify each of the current registered users.
"This milestone demonstrates our commitment to revolutionizing digital identity in Africa and beyond, made possible by our partnership with BIO-key, a leading biometric technology provider," said Aly Ramji, General Partner of Humanity International Investments.
The initiative has expanded to include a groundbreaking Community Staking program, engineered to function as a comprehensive ecosystem where Non-Fungible Tokens (NFTs) represent the identity of participants. Each NFT assigns a unique digital identity to each user but also facilitates a direct and transparent method for distributing economic returns.
With over 40,000 unique registered users across 94 countries, with a significant footprint in Nigeria, Kenya, and Vietnam, the Humanity Protocol demonstrates a sustainable model where community stakers back each participant. This backing is not just financial; it's a vote of confidence in the individuals' ability to contribute to and thrive within the digital economy.
"This innovative program is designed to provide financial benefits to participants, fostering a robust and financially inclusive community to those at the bottom of the pyramid across Africa and Asia", said Ramji.
The Humanity Protocol is pioneering a digital identity revolution, leveraging the potential of Africa's young and rapidly urbanizing population to ensure broader access to the decentralized digital economy. The community staking program is Humanity International Investment's commitment to inclusivity and security in the digital space.
For further inquiries with Humanity International Investment, please contact:
Communications@humanityinvestments.co
About Humanity International Investments (www.humanityinvestments.co)
Humanity International Investments is a Dubai-based social impact fund dedicated to fostering financial inclusion across Africa. With an expansive network spanning the continent, the organization is committed to bridging the identity gap for the unbanked and the ultra-poor. By collaborating with innovative technology partners, the Humanity Protocol seeks to provide verifiable identities, enabling countless Africans to access financial services, credit, and opportunities for wealth creation. Their vision is not just about creating identities but about empowering individuals to change their futures and have a voice in the global digital community.
For further inquiries with Bio-Key International, please contact:
732.359.1100
info@bio-key.com
About BIO-key International, Inc. (www.BIO-key.com)
BIO-key is revolutionizing authentication and cybersecurity with biometric-centric, multi-factor identity and access management (IAM) software securing access for over thirty-eight million users. BIO-key allows customers to choose the right authentication factors for diverse use cases, including phoneless, tokenless, and passwordless biometric options. Its hosted or on-premise PortalGuard IAM solution provides cost-effective, easy-to-deploy, convenient, and secure access to computers, information, applications, and high-value transactions.
Media Contact Full Name: Jumal Lewis
Media Contact Company: Humanity International Investments
Media Contact Phone Number: 1 (917) 833-1830
Media Contact Website: https://humanityinvestments.co/
Media Contact Email: communications@humanityinvestments.co
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6cee45fb-9e83-405f-ba12-87270dc12bee
Quiet loading… let’s see if 7’s get taken out….
6’s ! Let’s go! … eom
Somebody bought a bunch of 5’s… will we see 6’s printing this week?
BonnieMac, You’re welcome… have a great week!
WALL, N.J., May 20, 2022 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring Identity-Bound Biometrics (IBB) and large-scale identity solutions, will participate in the H.C. Wainwright Global Investment Conference 2022. The company’s presentation will be available on demand beginning Tuesday, May 24th at 7am ET. BIO-key’s CEO Mike DePasquale will be available for virtual investor meetings on Wednesday, May 25th and Thursday, May 26th.
BonnieMac, I was able to find this in just three taps on my iPhone. I do not understand your difficulty navigating “X” …
We need to do better with shareholder engagement and communicating the value of our scientific milestones and their impact on disease diagnosis, treatment, and potential cure. This will change now. We are grateful for your continued faith and support. Onwards and Upwards
— Gaurav Chandra M.D. (@drgauravchandra) March 10, 2024
Dr. Chandra tweet: “We need to do better with shareholder engagement and communicating the value of our scientific milestones and their impact on disease diagnosis, treatment, and potential cure. This will change now. We are grateful for your continued faith and support. Onwards and Upwards.”
— healthbot (@thehealthb0t) March 9, 2024
BonnieMac, Enzolytics is just “flexing its muscles.” Charles will take the next deal waiting after the Sagaliam is fully gone. Patience has always been the avenue of success here for investors. JMHO GLTA!
Mutat, Charles will go with “any” deal that provides funding… NASDAQ, OTC, …
1jas, No, it’s not… eom
Delisted. Zero Bid/ Zero Ask. eom
The traders are swinging this one. RSI at 70… patience…
1hunglo, Good comment. … eom
SAGALIAM ACQUISITION CORP. ANNOUNCES DELISTING OF COMMON SHARES FROM NASDAQ
Sagaliam Acquisition Corp
March 07, 2024 09:35 ET
New York, NY, March 07, 2024 (GLOBE NEWSWIRE) -- Sagaliam Acquisition Corp. (NASDAQ: “SAGAU”, “SAGA”, SAGAR”) (the “Company”) received a Nasdaq Hearing Withdrawal letter (“Notice”) from the Listing Qualifications staff of the Nasdaq Stock Market LLC (“Nasdaq”) on March 6, 2024.
On May 26, 2023, Staff notified the Company that the market value of its listed securities had been below the minimum $50,000,000 required for continued listing as set forth in Listing Rule 5450(b)(2)(A) for the previous 30 consecutive trading days.1 Therefore, in accordance with Listing Rule 5810(c)(3)(C), the Company was provided 180 calendar days, or until November 22, 2023 to regain compliance with the Rule.
On November 27, 2023, the Company filed its delinquent Form 10-Q for the period ended March 31, 2023, disclosing total shares outstanding of 49,346,337. In addition, the Form 10-Q for the period ended March 31, 2023 was not reviewed by its independent auditors, Marcum LLP, and the Company intends to amend this filing. According to the Company’s December 1, 2023, response to a request for additional information, on September 15, 2023, the Company issued 47,872,000 shares of common stock in connection with the acquisition of Virogentics Inc. and Biogenysis, Inc. (the “Business Combination”’). At the time of the acquisition, the Company’s total shares outstanding was 1,471,337 shares. Staff notes that beyond the disclosure included in a Form 8-K filed September 15, 2023, announcing the entering into an agreement for the Business Combination, the Company failed to disclose the closing of the transaction and issuance of shares either to Nasdaq or to the public.
Following a review of the Company’s submission and public disclosures, Staff has determined that the Business Combination violated the following Listing Rules, with each serving as an additional and separate basis for delisting:
Listing Rule IM-5101-2(d) due to the Company’s failure to seek shareholder approval for the Business Combination, allow for shareholders to redeem shares in connection with the vote, and demonstrate compliance with Nasdaq initial listing requirements upon closing of the Business Combination;
Listing Rule 5635(a)(1) due to the Company’s failure to obtain shareholder approval in connection with an acquisition of stock or assets of another company where the issuance or potential issuance is greater than 20% of the total shares outstanding or voting power outstanding;
Listing Rule 5635(c) due to the Company’s failure to obtain shareholder approval in connection with an issuance resulting in a change of control;
Listing Rule 5250(b)(1) due to the Company’s failure to disclose material information; specifically, the closing of the Business Combination and issuance of more than 47 million shares;
Listing Rule 5250(e)(1) due to the Company’s failure to notify Nasdaq no later than 10 days after the increase of greater than 5% of the shares outstanding; and
Listing Rule 5250(e)(2) due to the Company’s failure to file the Notification Form: Listing of Additional Shares for an issuance of greater than 10% of the pre-transaction shares outstanding.
Separately, on October 24, 2023, Nasdaq notified the Company that is does not comply with the minimum 400 total holders requirement, as required by Listing Rule 5450(a)(2). Additionally, on August 23, 2023, Nasdaq notified the Company that it did not comply with Listing Rule 5250(c) due to its failure to timely file its Form 10-Q for the period ended June 30, 2023. The Company has also not filed its Form 10-Q for the period ended September 30, 2023. These failures to timely file periodic reports and maintain a minimum of 400 total holders each serve as additional and separate basis for delisting.
Finally, under Listing Rules 5101 and IM-5101-1, Nasdaq may “suspend or delist particular securities based on any event, condition, or circumstance that exists or occurs that makes initial or continued listing of the securities on Nasdaq inadvisable or unwarranted in the opinion of Nasdaq.” In light of the Company’s disregard for Nasdaq rules, as evidenced by its multiple violations of Nasdaq’s shareholder approval rules, ongoing failure to disclose material information and timely file periodic reports, and failure to comply with Nasdaq’s SPAC rule, Nasdaq has determined that the continued listing of the Company’s securities on Nasdaq is inadvisable and believes the delisting is appropriate to protect investors and the public interest.
Following is the core text of the letter received from Nasdaq on March 6, 2024:
This is to confirm Sagaliam Acquisition Corp.’s (the “Company”) withdrawal of its December 12, 2023, request for an appeal of the Nasdaq Listings Qualification staff’s delist determination dated December 5, 2023, for the Company’s failure to maintain compliance with the Exchange’s listing standards.
As a result of the Company withdrawing its appeal, its securities will be suspended at the open of business on March 8, 2024. Nasdaq will file a Form 25 Notification of Delisting with the U.S. Securities and Exchange Commission when all internal procedural periods have run.
The Company intends to work with OTC Markets to facilitate the continued trading of the Company’s shares on the OTC Markets.
On March 6, 2024, the Company filed its Form 10-Q for quarter ended September 30, 2023. In that filing, the Company did not sufficiently disclose that a review was not performed by its independent registered public accounting firm. According to the SEC Division of Corporate Finance Financial Reporting Manual, Section 4410.3: “If the review was not performed by a registered public accounting firm, the Form 10-Q is considered substantially deficient and not timely filed. In addition, the Form 10-Q must include the following disclosures:
a. Identify the report as deficient;
b. Label the columns of the financial statements as “not reviewed”; and
c. Describe how the registrant will remedy the deficiency.
When the review is completed by a registered accounting firm, the registrant must file an amendment to remove the references to the deficiency and the financial statements as “not reviewed.”
Management and the Audit Committee have discussed the matters disclosed pursuant to this item 4.02 with Marcum LLP, the Company’s independent registered public accounting firm.
The Company does not expect any of the above changes will have any impact on its cash position and cash held in the trust account.
The Company plans to amend its form 10-Q for the quarter ended September 30, 2023 to be filed with the SEC.
About Enzolytics
Enzolytics, Inc. is a drug development company committed to commercializing its proprietary proteins and monoclonal antibodies to treat debilitating infectious diseases. The Company is advancing multiple therapeutics targeting numerous infectious diseases. One patented and clinically tested compound, ITV-1 (Immune Therapeutic Vaccine-1), is a suspension of Inactivated Pepsin Fraction (IPF), covered by U.S. Patent Nos. 8,066,982 and 7,479,538. Studies have shown it to be effective in treating HIV/AIDS. ITV-1 has also been shown to modulate the immune system.
The Company has proprietary technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases which is currently being employed to produce monoclonal antibody therapeutics for treating the Coronavirus (SARS-CoV-2), HIV-1 and the Feline Leukemia virus. The Company has also identified conserved epitopes on and has plans to produce mAbs targeting many other viruses, including HIV-2, Influenza A and B, H1N1 influenza, Respiratory syncytial virus (RSV), Small-Pox, Ebola Virus, Tetanus, Diphtheria, HTLV-1/2, Rabies, Herpes zoster, Varicella zoster, Anthrax, Mason-Pfizer monkey virus (MPMV) and Visna virus (VISNA). The Company has also analyzed epitopes of animal viruses and plans to produce mAbs for treating these animal viruses.
About Sagaliam Acquisition Corp.
We are a blank check company incorporated under the laws of the State of Delaware on March 31, 2021 for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses or entities. Sagaliam intends to continue to pursue the consummation of a business combination with an appropriate target.
Forward Looking Statements
The disclosure herein includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics and projections of market opportunity and expectations, Company’s ability to enter into a definitive business combination agreement and Company’s ability to obtain the financing necessary to consummate the potential business combination transaction. These statements are based on various assumptions and on the current expectations of Company’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Company. These forward-looking statements are subject to a number of risks and uncertainties, including: Company’s ability to enter into a definitive agreement with respect to the proposed business combination or consummate a transaction; the risk that the approval of the stockholders of Company for the potential transaction is not obtained; failure to realize the anticipated benefits of the potential transaction, including as a result of a delay in consummating the potential transaction or difficulty in integrating the businesses of Company; the amount of redemption requests made by Company’s stockholders and the amount of funds remaining in Company’s trust account after satisfaction of such requests; those factors discussed in Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 under the heading “Risk Factors,” and other documents of Company filed, or to be filed, with the SEC. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Company presently does not know or that Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Company’s expectations, plans or forecasts of future events and views as of the date hereof. Company anticipates that subsequent events and developments will cause Company’s assessments to change. However, while Company may elect to update these forward-looking statements at some point in the future, Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Company’s assessments as of any date subsequent to the date of this disclosure statement. Accordingly, undue reliance should not be placed upon the forward-looking statements.
CONTACT INFORMATION
Sagaliam Acquisition Corp.,
Barry Kostiner, Chief Executive Officer
3002 Royal Palm
Baytown, Texas 77523
Tel: (845) 925-4597
bkostiner@fintecham.com
docsetc, Very generous of you to perform this service. Greatly appreciated!